Unknown

Dataset Information

0

Identification and Targeting of Thomsen-Friedenreich and IL1RAP Antigens on Chronic Myeloid Leukemia Stem Cells Using Bi-Specific Antibodies.


ABSTRACT:

Introduction

Quiescent leukemia stem cells (LSCs) play a major role in therapeutic resistance and disease progression of chronic myeloid leukemia (CML). LSCs belong to the primitive population; CD34+CD38-Lin-, which does not distinguish normal hematopoietic stem cells (HSC) from CML LSCs. Because Thomsen-Friedenreich/CD176 antigen is expressed on CD34+ HSC and IL1RAP is tightly correlated to BCR-ABL expression, we sought to increase the specificity towards LSC by using additional biomarkers.

Methods

We evaluated the co-expression of both antigens on CD34+ peripheral blood mononuclear cells (PBMCs) from both healthy volunteers and CML patients, using flow cytometry. Then, we used site-directed mutagenesis to induce knob-in-hole mutations in the human IgG heavy chain and the human lambda light chain to generate the bi-specific antibody (Bis-Ab) TF/RAP that binds both antigens simultaneously. We measured complement-directed cytotoxicity (CDC) in CML samples with the Bis-Ab by flow cytometry.

Results

In contrast to healthy volunteers, CML samples displayed a highly significant co-expression of CD176 and IL1RAP. When either a double-positive cell line or CML samples were treated with increasing doses of Bis-Ab, increased binding and CDC was observed indicating co-operative binding of the Bis-Ab as compared to monoclonal antibodies.

Discussion

These results show that the bi-specific antibody is capable of targeting IL1RAP+ and CD176+ cell population among CML PBMCs, but not corresponding normal cells in CDC assay. We hereby offer a novel strategy for the depletion of CML stem cells from the bulk population in clinical hematopoietic stem cell transplantation.

SUBMITTER: Eldesouki RE 

PROVIDER: S-EPMC7837560 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

altmetric image

Publications

Identification and Targeting of Thomsen-Friedenreich and IL1RAP Antigens on Chronic Myeloid Leukemia Stem Cells Using Bi-Specific Antibodies.

Eldesouki Raghda E RE   Wu Chengxiang C   Saleh Fayez M FM   Mohammed Eman Abdel-Moemen EA   Younes Soha S   Hassan Naglaa Elsayed NE   Brown Theresa C TC   Alt Eckhard U EU   Robinson James E JE   Badr Fouad Mohamed FM   Braun Stephen E SE  

OncoTargets and therapy 20210122


<h4>Introduction</h4>Quiescent leukemia stem cells (LSCs) play a major role in therapeutic resistance and disease progression of chronic myeloid leukemia (CML). LSCs belong to the primitive population; CD34+CD38-Lin-, which does not distinguish normal hematopoietic stem cells (HSC) from CML LSCs. Because Thomsen-Friedenreich/CD176 antigen is expressed on CD34+ HSC and IL1RAP is tightly correlated to BCR-ABL expression, we sought to increase the specificity towards LSC by using additional biomark  ...[more]

Similar Datasets

| S-EPMC4553807 | biostudies-other
| S-EPMC3616747 | biostudies-literature
| S-EPMC4307422 | biostudies-literature
| S-EPMC3566327 | biostudies-literature
| S-EPMC7128052 | biostudies-literature
| S-EPMC10616308 | biostudies-literature
| S-EPMC5920613 | biostudies-literature
| S-EPMC8684082 | biostudies-literature
| S-EPMC7866256 | biostudies-literature
| S-EPMC8708315 | biostudies-literature